96 related articles for article (PubMed ID: 19435643)
41. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.
Niibe Y; Nakayama M; Matsubayashi T; Takahashi H; Kitano M; Okamoto M; Hayakawa K
Anticancer Res; 2007; 27(5B):3497-500. PubMed ID: 17972507
[TBL] [Abstract][Full Text] [Related]
43. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
[TBL] [Abstract][Full Text] [Related]
44. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
[TBL] [Abstract][Full Text] [Related]
45. [S-1 activity in non-small cell lung cancer in clinical practice].
Inagaki M; Onuki T; Iguchi K; Ogata T; Hayashi Y; Saito K; Wakai Y; Takabe K; Shinohara Y; Suzuki K; Ohtani T; Horikoshi K
Gan To Kagaku Ryoho; 2009 May; 36(5):763-7. PubMed ID: 19461174
[TBL] [Abstract][Full Text] [Related]
46. Results of combined modality treatment for nasopharyngeal cancer.
Venkitaraman R; Ramanan SG; Vasanthan A; Sagar TG
J Cancer Res Ther; 2009; 5(2):102-6. PubMed ID: 19542665
[TBL] [Abstract][Full Text] [Related]
47. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience.
Jurado M; Alcázar JL; Martinez-Monge R
Gynecol Oncol; 2010 Jan; 116(1):38-43. PubMed ID: 19878978
[TBL] [Abstract][Full Text] [Related]
48. Interstitial brachytherapy as boost for locally advanced T4 head and neck cancer.
Do L; Puthawala A; Syed N
Brachytherapy; 2009; 8(4):385-91. PubMed ID: 19733128
[TBL] [Abstract][Full Text] [Related]
49. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland.
Sharp L; Carsin AE; Cronin-Fenton DP; O'Driscoll D; Comber H
Eur J Cancer; 2009 May; 45(8):1450-9. PubMed ID: 19268569
[TBL] [Abstract][Full Text] [Related]
50. Multimodality treatment of mesenteric desmoid tumours.
Bertagnolli MM; Morgan JA; Fletcher CD; Raut CP; Dileo P; Gill RR; Demetri GD; George S
Eur J Cancer; 2008 Nov; 44(16):2404-10. PubMed ID: 18706807
[TBL] [Abstract][Full Text] [Related]
51. Serum ferritin predicted prognosis in patients with locally advanced pancreatic cancer.
Wang SL; Cao S; Wu R; Chi F; Tang MY; Jin XY; Chen XD
Future Oncol; 2015; 11(21):2905-10. PubMed ID: 26436474
[TBL] [Abstract][Full Text] [Related]
52. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer.
Sui K; Okabayashi T; Shima Y; Morita S; Iwata J; Sumiyoshi T; Saisaka Y; Hata Y; Noda Y; Matsumoto M; Nishioka A; Iiyama T; Shimada Y
Br J Radiol; 2017 Jul; 90(1075):20170165. PubMed ID: 28590776
[TBL] [Abstract][Full Text] [Related]
53. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity.
Hatfield P; Hingorani M; Radhakrishna G; Cooper R; Melcher A; Crellin A; Kwok-Williams M; Sebag-Montefiore D
Radiother Oncol; 2009 Aug; 92(2):210-4. PubMed ID: 19409638
[TBL] [Abstract][Full Text] [Related]
54. Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy.
Takemura N; Kokudo N; Imamura H; Takazawa Y; Sano K; Sugawara Y; Nakagawa K; Ohtomo K; Makuuchi M
Hepatogastroenterology; 2008; 55(88):1997-9. PubMed ID: 19260466
[TBL] [Abstract][Full Text] [Related]
55. [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
Kai K; Endo Y; Yoshida K; Morikawa T; Nobuhisa T; Watanabe T; Matsumoto Y; Yamada T; Doi Y; Nakashima A; Nagahiro W; Ishizuka S; Sato S; Nakashima A; Nabeyama A
Gan To Kagaku Ryoho; 2008 Feb; 35(2):339-41. PubMed ID: 18281779
[TBL] [Abstract][Full Text] [Related]
56. Long-term postoperative adjuvant chemotherapy of UFT/LV improves survival in a primary tumor resection-pulmonary metastasis model.
Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Makuuchi H; Kamijo A; Murayama C
Anticancer Res; 2008; 28(4B):2045-8. PubMed ID: 18751373
[TBL] [Abstract][Full Text] [Related]
57. Margin clearance and outcome in resected pancreatic cancer.
Chang DK; Johns AL; Merrett ND; Gill AJ; Colvin EK; Scarlett CJ; Nguyen NQ; Leong RW; Cosman PH; Kelly MI; Sutherland RL; Henshall SM; Kench JG; Biankin AV
J Clin Oncol; 2009 Jun; 27(17):2855-62. PubMed ID: 19398572
[TBL] [Abstract][Full Text] [Related]
58. Impact of presence and degree of pretreatment weight loss in locally-advanced pancreatic cancer patients treated with definitive concurrent chemoradiotherapy.
Yildirim BA; Özdemir Y; Colakoglu T; Topkan E
Pancreatology; 2016; 16(4):599-604. PubMed ID: 27029854
[TBL] [Abstract][Full Text] [Related]
59. [Cardiac toxicity and UFT].
Marcos Sánchez F; Albo Castaño I; Arbol Linde F; Juárez Ucelay F; Durán Pérez-Navarro A
An Med Interna; 2003 Jan; 20(1):50. PubMed ID: 12666313
[No Abstract] [Full Text] [Related]
60. Palliative radiotherapy in paediatric malignancies.
Bhasker S; Bajpai V; Turaka A
Singapore Med J; 2008 Dec; 49(12):998-1001. PubMed ID: 19122950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
